Find your next paid study

National Cancer Institute (NCI)NCT06694454

~$10 – $5,625

Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in co…

Marengo Therapeutics, Inc.NCT05592626

Phase 2

Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

This clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works bet…

NSCLC (Advanced Non-small Cell Lung Cancer)

Multitude Therapeutics Inc.NCT07718737

Endometrial CancerOvarian CancerOvarian Cancer Metastatic+4 more

A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conj…

Whitehawk Therapeutics, Inc.NCT07444814

NSCLC (Advanced Non-small Cell Lung Cancer)

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity …

BlossomHill TherapeuticsNCT06706076

Observational

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III…

Stage II Lung CancerLung CancerNon-small Cell Lung Cancer+1 more

Dana-Farber Cancer InstituteNCT07412041

~$10 – $7,500

Phase 3

A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs gr…

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Particip…

High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combinati…

Advanced Solid TumorsMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)+3 more

Revolution Medicines, Inc.NCT07397338

Advanced/Metastatic Solid TumorsColorectal CancerGastric Cancer+5 more

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MC…

Small Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC)

~$10 – $7,500

Merus B.V.NCT03526835

Phase 2

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tum…

Bindu R PotugariNCT07339059

~$10 – $7,500

NSCLC Stage IVALK Fusion Protein Expression

Pilot Study of a Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients c…